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Abstract
In many developed countries, the burden of disease has shifted from acute to long-term or chronic diseases – 
producing new and broader challenges for patients, healthcare providers, and healthcare systems. Multimorbidity, 
the coexistence of two or more chronic diseases within an individual, is recognized as a significant public health 
and research priority. This protocol aims to examine the prevalence, characteristics, and changing burden of mul-
timorbidity among adult primary healthcare (PHC) patients using electronic medical record (EMR) data. The 
objectives are two-fold: (1) to measure the point prevalence and clusters of multimorbidity among adult PHC 
patients; and (2) to examine the natural history and changing burden of multimorbidity over time among adult 
PHC patients. Data will be derived from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN). 
The CPCSSN database contains longitudinal, point-of-care data from EMRs across Canada. To identify adult 
patients with multimorbidity, a list of 20 chronic disease categories (and corresponding ICD-9 codes) will be used. 
A computational cluster analysis will be conducted using a customized computer program written in JAVA. A Cox 
proportional hazards analysis will be used to model time-to-event data, while simultaneously adjusting for pro-
vider- and patient-level predictors. All analyses will be conducted using STATA SE 13.1. This research is the first 
of its kind using a pan-Canadian EMR database, which will provide an opportunity to contribute to the inter-
national evidence base. Future work should systematically compare international research using similar robust 
methodologies to determine international and geographical variations in the epidemiology of multimorbidity.
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Introduction
In many developed countries, populations are experi-
encing a transition, where the burden of illness is shifting 
from acute to long-term or chronic diseases – produc-
ing new and broader challenges for patients, healthcare 
providers, and healthcare systems [1,2]. The progressive 
Multimorbidity in Canada: protocol  151
© 2015 The Authors
 Published by Swiss Medical Press GmbH | www.swissmedicalpress.com Journal of Comorbidity 2015;5:150–161
aging of individuals, improved medical services, and 
advancing health technologies have led to increased 
survival among patients with chronic disease. While 
this is a success of modern medicine, this increased sur-
vival has resulted in growing numbers of patients living 
with multiple chronic diseases and experiencing greater 
healthcare needs [3–10]. Multimorbidity, the coexis-
tence of multiple chronic diseases within an individual, 
is now recognized as a significant health system cost and 
a major public health and research priority [6,9,11–15].
Although the prevalence of multimorbidity increases 
substantially with age, this phenomenon is increasingly 
being seen in younger populations, as recent studies 
have found larger absolute numbers of primary health-
care (PHC) populations under the age of 65 years living 
with multimorbidity [4,8]. Generally, a PHC popula-
tion consists of patients seeking integrated and accessible 
care from a practitioner who: (1) is the first level of con-
tact with the healthcare system; (2) addresses the large 
majority of personal healthcare needs; and (3) develops 
a sustained partnership with patients in the context of 
family and community [16,17]. Multimorbidity is rec-
ognized as the norm, rather than the exception, in PHC 
populations [10,18]. In fact, the focus of PHC in many 
developed countries, including Canada, is principally 
centered on the treatment and management of chronic 
diseases, which are often occurring in multiples. Deemed 
an “endless struggle” by PHC providers, patients experi-
encing multimorbidity require an integrated healthcare 
system that adequately responds to their complex and 
changing needs [19,20]. These patients represent unique 
clinical profiles, suffering from distinct combinations of 
chronic diseases, which can escalate the challenge for 
providers [21–23]. Clinical and epidemiologic research 
has yet to provide robust data and evidence on multi-
morbidity, comparable to information that is readily 
available for single chronic diseases [24]. Enhanced 
understanding of multimorbidity prevalence, charac-
teristics, determinants, and prognosis over time is still 
needed.
Multimorbidity has been conceptualized in many 
different ways in previous literature, and to date, no 
“gold standard” measure of multimorbidity has been 
established. Diederichs et al. [25] conducted a system-
atic review that identified 39 different multimorbidity 
measures. Some measures are based on simple counts 
of chronic diseases (with considerable variation in the 
“list” of diseases used), while other measures differen-
tially weight diseases to account for burden of illness or 
number of body systems affected [25,26]. Many com-
monly used measures of multimorbidity were originally 
developed and validated among elderly patient popula-
tions or hospital-based populations [27]. The marked 
variation in study methodologies has produced differing 
prevalence estimates, even among similar PHC popula-
tions. In a recent comparison of three studies examining 
the prevalence of multimorbidity, prevalence levels 
reported among PHC patients ranged from 34% to 95%, 
indicating as much as 61% variation in estimates [24]. 
Not only does this persistent heterogeneity in meth-
odology create incomparable research findings, it also 
hinders the ability to make informed health system and 
health policy decisions [11,24].
To contribute to the growing international evidence 
base, a national study examining the prevalence and 
patterns of multimorbidity from the Canadian PHC per-
spective will be conducted. Although principally used 
for clinical purposes, electronic medical records (EMRs) 
can provide rich insight for academic researchers. These 
clinical data contain longitudinal, patient-level informa-
tion that present a unique opportunity to examine both 
the onset and changing burden of multimorbidity over 
time [3,6]. The protocol described herein aims to capi-
talize on this opportunity. This research will examine 
the burden of multimorbidity among adult PHC patients 
in Canada, through the use of EMR data.
Objectives
The objectives of this research are two-fold. Both 
objectives will contribute to the understanding of multi-
morbidity in PHC, using a national EMR database. The 
first objective is to measure the point prevalence and 
clusters of multimorbidity among adult PHC patients. 
This objective will aim to understand the overall bur-
den of multimorbidity among adult PHC patients, as 
well as the most frequently occurring permutations and 
combinations of chronic disease diagnoses. The second 
objective is to examine the natural history and chang-
ing burden of multimorbidity over time among adult 
PHC patients. This objective will examine the time-
to-event patterns of multiple chronic disease diagnoses, 
accounting for both provider- and patient-level baseline 
predictors.
Methods
Study design
The key methodologic considerations that should be 
explicitly described in cross-sectional and retrospec-
tive cohort studies examining multimorbidity are 
defined as the “Methods Crystals for Multimorbidity” 
by  Stewart et al. [24]. These elements have been notably 
absent in previously published multimorbidity literature, 
yet are important to ensure comparable and transpar-
ent findings. Following the “Methods Crystals for 
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Multimorbidity” structure, the main study design ele-
ments for this research protocol are described more fully 
in Table 1 [28–30]. While clinical events and encounters 
with patients are recorded in the EMR prospectively by 
PHC providers, this research will utilize a retrospective 
or historic cohort design using existing EMR data. To 
be included in both objectives, individuals must have at 
least one in-office encounter date recorded in the EMR 
and be identified as “adult” patients (at least 18 years 
of age) as of their first encounter date. Those patients 
who are under the age of 18 years at their first encounter 
date or who do not have a detectable in-office encounter 
recorded in the EMR will be excluded. Those patients 
who have opted-out of contributing their data to the 
EMR database will also be excluded from analyses. 
Ethical approval has been obtained from the Research 
Ethics Board at Western University (Approval Notice 
#104705).
Data source
For both objectives, data will be derived from the 
Canadian Primary Care Sentinel Surveillance Network 
(CPCSSN). The CPCSSN database contains longitudi-
nal, point-of-care data from EMRs, which are extracted 
on a quarterly basis by CPCSSN data managers from 
participating PHC practices [31,32]. These data are then 
de-identified, cleaned, coded, and transformed into a 
common data format for compilation into the secure 
CPCSSN database. As of the data extraction period for 
this research (September 30, 2013), a total of 600,265 
de-identified electronic patient records were collected 
from 475 PHC providers, referred to as “sentinels” by 
CPCSSN, in 10 regional networks across Canada. The 
CPCSSN data elements that will be used contain infor-
mation on practice characteristics (e.g. geographical 
location); provider characteristics (e.g. provider birth 
year, provider sex); patient characteristics (e.g. patient 
birth year, patient sex, first three letters of residential 
postal code); and in-office encounters (e.g. encoun-
ter date, billing diagnosis codes, encounter diagnosis 
codes). The majority (approximately 95%) of diagnostic 
codes within the CPCSSN database are recorded using 
the International Classification of Disease, 9th Revision 
(ICD-9) system. As such, these codes will be used to 
identify chronic disease diagnoses.
Identifying chronic disease diagnoses
Within the CPCSSN EMR data, there are two potential 
sources of diagnostic codes that are accessible for research 
purposes. These two sources are the Billing Diagnosis 
Codes and the Encounter Diagnosis Codes. Both sets of 
diagnosis codes are recorded using the ICD-9 system, 
by administrative staff or PHC providers (e.g. nurses, 
nurses practitioners, medical residents, family physi-
cians), to reflect the patient’s ongoing health status. 
Each diagnostic code is documented with an associ-
ated date (day, month, and year) on which the diagnosis 
occurred. Initial data exploration indicated variation in 
where the majority of diagnosis codes were recorded, 
between these two sources. For example, some practice 
sites and/or providers primarily use the Billing Diag-
nosis Codes to record information, while others use the 
Encounter Diagnosis Codes to do so. Consequently, to 
capture the maximum amount of data from the patient 
record, the average number of Billing Diagnosis Codes 
(total number of billing diagnosis codes divided by the 
total number of patient encounters) and the average 
number of Encounter Diagnosis Codes (total number of 
encounter diagnosis codes divided by the total number 
of patient encounters) will be calculated on a patient-by-
patient basis. The source (Billing Codes or Encounter 
Codes) with the larger average number of diagnostic 
codes will be selected for each patient. In addition to 
using the maximum amount of diagnostic information 
and avoiding duplicate diagnoses, this approach will also 
address the variability in diagnostic recording at the 
patient, provider and practice levels.
Identifying patients with multimorbidity
To identify adult patients with multimorbidity, we will 
use a list of 20 chronic disease categories (and corre-
sponding ICD-9 codes) created by a nationally funded 
(Canadian Institutes of Health Research) research 
project examining Patient-Centred Innovations for 
Persons with Multimorbidity (PACE in MM). This 
 community-based primary healthcare (CBPHC) project 
aims to improve the delivery of appropriate, high-qual-
ity, and patient-centered interventions to those with 
multimorbidity [33,34]. The list was created based on 
the international literature that examined the burden of 
multimorbidity among PHC patients, particularly using 
comprehensive national EMRs [6,8,25,35–40]. The 20 
chronic disease diagnoses in the list are particularly rel-
evant in clinical and general populations in Canada. In 
a separate study, this list will also be validated to ensure 
it is fully capturing the complex concept of multimor-
bidity. The complete list of chronic disease categories, 
as well as corresponding ICD-9 disease codes, are 
presented in Table 2. In some categories, overlapping 
ICD-9 codes are presented to ensure that all relevant 
codes are captured. For example, in the disease category 
“Thyroid problem”, a range of disease codes, as well as 
the individual codes, are presented and can be included. 
The comparison with previously used lists in multimor-
bidity research is presented in Table 3 [4,8,25,35–48].
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Data analyses
The first objective will examine the overall burden of 
multimorbidity in terms of its point prevalence and the 
clusters of multiple chronic disease diagnoses that tend 
to occur together. For this objective, patients will be fol-
lowed over time and each chronic disease diagnoses (from 
the list of 20) received by each patient will be identified. 
Patient characteristics (e.g. patient age, patient sex, and 
residential location) will be compared with the broader 
CPCSSN PHC population, as well as with the general 
adult Canadian population. Prevalence estimates will be 
calculated using mutually exclusive count numerators 
(e.g. patients with 2, 3, 4, and 5 or more chronic dis-
eases) and for each calculation, the denominator will be 
all eligible adult PHC patients (N=367,743). Prevalence 
estimates, and corresponding 95% confidence inter-
vals, will be calculated using the proportion procedure 
in STATA SE 13.1 [49]. These estimates will be strati-
fied by patient age and sex categories, as well as provider 
age and sex categories, to investigate distinct patterns of 
multimorbidity. Additionally, prevalence estimates will 
be stratified by the patient’s residential location, which 
will be determined using the patient’s forward sorta-
tion area. More specifically, the second character of the 
patients’ postal code will determine their residence in a 
rural (second character is a zero) or urban (second char-
acter is a value from one to nine) setting as defined by 
Canada Post. Among patients with multimorbidity, the 
frequency of ordered and unordered clusters of chronic 
disease types will be computed using a customized com-
puter program written in JAVA. The most commonly 
occurring combinations and permutations of chronic 
diseases will be presented.
The second objective will examine the time-to-event 
patterns of multimorbidity by observing the time elaps-
ing between subsequent chronic disease diagnoses. For 
this objective, patients with at least one chronic disease 
diagnosis will be included and four patient groups will 
be created: (1) patients with one or more chronic dis-
ease diagnoses by the end of the observation period; (2) 
patients with two or more chronic disease diagnoses by 
the end of the observation period; (3) patients with three 
or more chronic disease diagnoses by the end of the 
observation period; and (4) patients with four or more 
chronic disease diagnoses by the end of the observation 
period. The details of these patient groups are depicted 
in Figure 1. The event of interest will be the next 
chronic disease diagnosis (regardless of diagnosis type). 
Survival analysis techniques allow for staggered entry 
dates of patients into the study, as well as right censoring 
if a patient does not experience the event of interest by 
the end of the observation period. This will maximize 
the amount of information contributed by each patient. 
For all patient groups, the end of the observation period 
will be September 30, 2013 (date of Q3-2013 extract). A 
=  Start of patient observation period
    (unique for each patient group)
=  Start of EMR data collection
=  Event of interest
    (next chronic disease diagnosis)
X1  =  Index chronic disease diagnosis
X2  =  Second chronic disease diagnosis
X3  =  Third chronic disease diagnosis
X4  =  Fourth chronic disease diagnosis
X5  =  Fifth chronic disease diagnosis
=  Right censoring (no event)
Patient A
Patient B
Patient C
Patient
group 1
Patient D
Patient E
Patient F
Patient
group 2
Patient G
Patient H
Patient I
Patient
group 3
Patient J
Patient K
Patient L
Patient
group 4
X1
X4
X2
X3
X1
X3
X1
X3
X3
X1 X2
X1 X2
X1
X2
X1 X2
X2
X4
X1 X2
X3 X4
X1 X2 X3
X1 X2 X5
X1 X2 X3 X4 X5
X3X1 X2 X4
End of observation period
(September 30, 2013)
Patient group 1  =  Patients with ≥1 chronic disease
Patient group 2  =  Patients with ≥2 chronic diseases
Patient group 3  =  Patients with ≥3 chronic diseases
Patient group 4  =  Patients with ≥4 chronic diseases
Legend:
Figure 1 Examples of Objective 2 patient groups, as well as corresponding start and end of observation periods for time-to-event analyses. EMR, 
electronic medical record.
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Cox proportional hazards analysis will be used to model 
time-to-event data, while simultaneously adjusting for 
provider- and patient-level predictors, and account-
ing for issues such as patient attrition or delayed entry 
into observation [50,51]. The Cox proportional hazards 
analysis will be conducted using the stcox procedure in 
STATA SE 13.1 [49], and the effects of clustering will 
be accounted for using a robust variance estimator. Each 
Cox proportional hazards model will then be built with 
the provider- and patient-level covariates that report 
p-values of <0.2 in univariate analyses. Interactions 
among included covariates will be explored, includ-
ing relevant interaction terms (at a significance level 
of 0.05) in the final Cox proportional hazards model. 
The proportional hazards assumption that is inherent 
in Cox models will be assessed by including time-
dependent covariates in the model by using the tvc and 
the texp options in the stcox procedure. Time-dependent 
covariates capture interaction of covariates and time. If 
non-significant, the proportionality assumption is main-
tained by that covariate. Schoenfeld residuals will also 
be explored using the stphtest procedure, in which the 
proportionality of the model as a whole and the pro-
portionality for each predictor will be assessed. Once 
again, non-significant tests indicate no violation of pro-
portionality assumption.
Discussion
Anticipated challenges
There are three anticipated challenges of this research: 
(1) degree of completeness, correctness, and compre-
hensiveness of the EMR data; (2) limited availability of 
socioeconomic variables in the EMR data; and (3) the 
limited generalizability of research findings to the gen-
eral Canadian population. The first challenge has been 
well recognized in work that has examined the benefits 
and limitations of EMR data, particularly for clinical 
and epidemiologic research [52]. Incomplete or missing 
data are often a limitation of using EMRs for research, 
primarily because EMRs are designed to support clini-
cal care delivery and are not structured in a way that 
easily facilitates use in research [53–55]. Incomplete or 
free-text data entry by providers may underestimate 
the prevalence of chronic diseases within the CPCSSN 
database as these data entries are not included in data 
extraction or final analysis. This may be particularly 
true for those diseases with less clear diagnostic fea-
tures, such as asthma or depression [56,57]. Before being 
entered into the final statistical analyses, variables will 
be assessed for missingness and outliers that may indicate 
inaccurate data recording.
The second challenge is the lack of availability of 
sociodemographic variables (e.g. patient ethnicity, edu-
cation level, employment status, income level) within the 
Canadian EMRs. When recorded, these variables often 
contain incomplete data that cannot be used reliably in 
statistical analyses. This represents an important limita-
tion as previous literature has highlighted the impact of 
social deprivation (e.g. low income level, low education 
level, unemployment, barriers to housing) on the devel-
opment of multimorbidity, particularly at younger ages 
[3,4,8]. Although each patient’s age, sex, and residential 
location will serve as patient-level predictors of multi-
morbidity, these variables will not completely account 
for the socioeconomic factors impacting health. This is 
indeed an area that requires further attention from pro-
viders using EMRs for clinical care.
The third anticipated challenge is that the CPCSSN 
database does not contain comprehensive data for the 
entire Canadian population and, therefore, does not 
represent the burden of multimorbidity for the general 
adult population in Canada. The CPCSSN database is 
made up of a selected sample of PHC providers who 
use EMRs, as well as the patients of these provid-
ers. A recent study compared the characteristics of the 
CPCSSN providers with the respondents of the 2010 
National Physician Survey; in which a higher proportion 
of CPCSSN PHC providers were women and slightly 
younger in age, while the geographic distribution of 
the providers was similar to the national characteristics 
[58]. Likewise, the representativeness of the CPCSSN 
population was assessed. While this study will compare 
the characteristics of the adult PHC patients with the 
characteristics of the broader adult population, in order 
to determine the degree of generalizability and repre-
sentativeness of the CPCSSN data, the eventual findings 
will specifically present the burden of multimorbidity in 
the PHC setting.
Anticipated strengths
This research is the first of its kind using a national 
EMR database, which will provide needed insight 
and an opportunity to contribute to the international 
evidence base. Although this clinical information is 
not principally recorded for research purposes, the 
CPCSSN database has recently become more acces-
sible to academic researchers for use in innovative 
projects relevant to CPCSSN’s mission and vision. 
These data represent the only pan-Canadian EMR 
database and are recognized as a rich source of PHC 
information. The previously described approach of 
identifying chronic disease diagnoses on a patient-
by-patient basis will maximize the amount of clinical 
information derived from each patient’s electronic 
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record, providing insight into PHC beyond what is 
typically gained from population surveys, administra-
tive databases, and billing information. Furthermore, 
the computational techniques to determine the most 
frequently occurring combinations and permutations 
of multiple chronic diseases will be made accessible to 
other multimorbidity researchers, with the potential 
for similar international work.
Anticipated research outcomes
The first objective will allow for comparisons with 
international prevalence estimates of multimorbidity 
and its associated burden; while the second objective 
will address an important and noted gap in understand-
ing the prognosis of multimorbidity using longitudinal 
clinical data. The list of 20 chronic diseases for our mul-
timorbidity definition is in accordance with a recent 
systematic review, which recommended that inves-
tigators “should consider the number of diagnoses to 
be assessed (with at least twelve frequent diagnoses of 
chronic diseases appearing ideal) and should attempt to 
report results for differing definitions of multimorbidity 
(both at least three disease and the classic at least two 
diseases)” [11]. Finally, this protocol responds to the call 
for publication of protocols in multimorbidity research 
and aims to support the transparency, reproducibility, 
and replication of this research methodology [59]. This 
could facilitate the creation of comparable estimates 
of multimorbidity across patient populations, both in 
 Canada and abroad.
Anticipated clinical- and policy-level impact
This research will have both clinical and policy rel-
evance. The complexities of multimorbidity create 
heterogeneity in the experiences of patients as they 
cope with and receive clinical management for their 
multiple chronic diseases. This is further compli-
cated by the heterogeneity in the clinical profile, or 
disease combination, each patient experiences. Com-
bined with the current lack of evidence-based clinical 
practice guidelines that facilitate patient-centered and 
coordinated care, these complex clinical pathways and 
clinical profiles have significant implications for health-
related outcomes and use of healthcare resources. As 
such, national multimorbidity estimates will help 
to inform where the redevelopment of clinical prac-
tice guidelines must focus to have the greatest clinical 
impact. From a public health or health policy perspec-
tive, the growing burden of multimorbidity consumes 
considerable societal and economic resources, and neg-
atively impacts satisfaction with care delivery, quality 
of life, and productivity of patients and their caregiv-
ers. Examining the most frequently occurring clusters 
of chronic disease, and patients who are most at risk of 
subsequent chronic disease diagnoses, can help inform 
the development of clinical- or population-level inter-
ventions to relieve this tsunami of health demands and 
to provide robust support needed by all stakeholders 
[12,18,24,60].
Conclusion
This protocol aims to examine the prevalence and 
changing burden of multimorbidity among adult 
PHC patients using EMR data. As electronic records 
are increasingly being used for academic research and 
health system planning, these data must be managed 
and analyzed properly. The findings of this research 
will be disseminated through publication and presen-
tation to academic researchers, decision-makers, and 
healthcare professionals. Future work should system-
atically compare international research using similar 
methodologies (e.g. definitions of multimorbidity, data 
sources, populations of interest) to explore international 
and geographical variations in the epidemiology of 
multimorbidity. Finally, a concerted and multifaceted 
effort must be made to establish effective and patient- 
centered interventions that help to alleviate the burden 
of multi morbidity for patients, caregivers, and health-
care providers into the future.
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